CardioGenesis revives hopes for heart laser
This article was originally published in Clinica
CardioGenesis has submitted new clinical data to support an application to market in the US its version of a controversial laser-heart therapy for angina. The amended submission is a rebuttal to an earlier knock-back from the US FDA and moves forward the unsettled debate over the proven safety and effectiveness of the technology.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.